Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c, Raises FY Guidance
November 5, 2019 4:22 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.10, $0.51 better than the analyst estimate of $3.59. Revenue for the quarter came in at $538 million versus the consensus estimate of $524.39 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $15.50-$16.15, versus the consensus of $15.03.... More
